TFRC and cancer: The therapeutic concept of the study is aiming at the targeted extracellular membrane protein degradation in cancer cells using a newly designed heterobispecific antibody chimera, which is carrying anti-POI binding as well as bivalent anti-transferrin receptor 1 (TfR1) binding domains connected via cathepsin B-cleavable Fc dimers.